Free Trial

Aura Biosciences (AURA) Stock Price, News & Analysis

+0.27 (+3.90%)
(As of 06/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
137,223 shs
Average Volume
173,200 shs
Market Capitalization
$356.69 million
P/E Ratio
Dividend Yield
Price Target

Aura Biosciences MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
191.7% Upside
$21.00 Price Target
Short Interest
7.36% of Float Sold Short
Dividend Strength
News Sentiment
0.64mentions of Aura Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.80) to ($1.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.04 out of 5 stars

Medical Sector

751st out of 896 stocks

Biological Products, Except Diagnostic Industry

126th out of 149 stocks

AURA stock logo

About Aura Biosciences Stock (NASDAQ:AURA)

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

AURA Stock Price History

AURA Stock News Headlines

Exposed: 3 CENT Crypto to Explode June 24th?
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…
Exposed: 3 CENT Crypto to Explode June 24th?
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…
Recap: Aura Biosciences Q4 Earnings
BTIG Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)
See More Headlines
Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$4.58 per share


Free Float
Market Cap
$356.69 million
Not Optionable
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Elisabet de los Pinos Ph.D. (Age 51)
    Founder, CEO, President & Director
    Comp: $795.3k
  • Ms. Julie B. Feder (Age 54)
    CFO, Secretary & Treasurer
    Comp: $505.45k
  • Mr. Patrick Nealon
    Senior Vice President of Clinical Development Operations
  • Dr. Bruce Brown M.D.
    Senior VP & Therapeutic Area Head of Urologic Oncology
  • Dr. Anthony Daniels M.D.
    Therapeutic Area Head of Ocular Oncology
  • Dr. Richard Mountfield Ph.D.
    Senior Vice President of Regulatory Affairs & Quality

AURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Aura Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AURA shares.
View AURA analyst ratings
or view top-rated stocks.

What is Aura Biosciences' stock price target for 2024?

3 brokers have issued 12-month price targets for Aura Biosciences' shares. Their AURA share price targets range from $19.00 to $23.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 191.7% from the stock's current price.
View analysts price targets for AURA
or view top-rated stocks among Wall Street analysts.

How have AURA shares performed in 2024?

Aura Biosciences' stock was trading at $8.86 on January 1st, 2024. Since then, AURA shares have decreased by 18.7% and is now trading at $7.20.
View the best growth stocks for 2024 here

Are investors shorting Aura Biosciences?

Aura Biosciences saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 2,870,000 shares, an increase of 6.3% from the May 15th total of 2,700,000 shares. Based on an average daily volume of 197,800 shares, the short-interest ratio is presently 14.5 days. Approximately 7.4% of the shares of the stock are sold short.
View Aura Biosciences' Short Interest

When is Aura Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our AURA earnings forecast

How were Aura Biosciences' earnings last quarter?

Aura Biosciences, Inc. (NASDAQ:AURA) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.11.

What ETFs hold Aura Biosciences' stock?

ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR).AltShares Event-Driven ET (EVNT).

When did Aura Biosciences IPO?

Aura Biosciences (AURA) raised $81 million in an initial public offering on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share.

Who are Aura Biosciences' major shareholders?

Aura Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.41%), Regency Capital Management Inc. DE (1.59%), Price T Rowe Associates Inc. MD (1.20%), Levin Capital Strategies L.P. (0.22%), Virtu Financial LLC (0.04%) and American International Group Inc. (0.04%). Insiders that own company stock include Cadmus Rich, David Michael Johnson, Julie B Feder, Los Pinos Elisabet De, Matrix Capital Management Comp and Rosch Mark De.
View institutional ownership trends

How do I buy shares of Aura Biosciences?

Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AURA) was last updated on 6/23/2024 by Staff

From Our Partners